 |
20 Diseases |  |
18 Trials |
|
18 Trials |  |
1690 News |  |
| «12...891011121314151617181920» |
- | Clinical, Journal: A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma. (Pubmed Central) - Jul 11, 2019
Brain biopsy tissue was also unobtainable during sequence of ALK due to risk versus benefit, which would have provided insight as which type of ALK resistance mutations the patient was developing. It is likely that this patient had some form of chromoplexy occurring.
- | Zykadia (ceritinib) / Novartis
Enrollment closed, Enrollment change, Trial primary completion date: Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 10, 2019
P1, N=57, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
It is likely that this patient had some form of chromoplexy occurring. Recruiting --> Active, not recruiting | N=86 --> 57 | Trial primary completion date: Feb 2019 --> Jun 2020
- | Zykadia (ceritinib) / Novartis
Trial completion date, Metastases: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib (clinicaltrials.gov) - Jul 9, 2019
P3, N=232, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=86 --> 57 | Trial primary completion date: Feb 2019 --> Jun 2020 Trial completion date: May 2021 --> Nov 2021
- | Clinical, Review, Journal: Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. (Pubmed Central) - Jun 30, 2019
Furthermore, third-generation inhibitors are currently under development to overcome acquired resistance mechanisms inevitably resulting from treatment with first- and second-generation tyrosine kinase inhibitors. Therefore, this article aims to provide a comprehensive state-of-the-art review about the pharmacodynamics, pharmacokinetics, safety, and tolerability profiles of currently available and promising under-development anaplastic lymphoma kinase tyrosine kinase inhibitors.
- |||| Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged #nsclc #lungcancer @notahedge @DavidHongMD @MDAndersonNews https://t.co/wnwgEIxofp (Twitter) - Jun 29, 2019
- | Avastin (bevacizumab) / Roche
Journal: System Biology Approach to Identify Potential Receptor for Targeting Cancer and Biomolecular Interaction Studies of Indole[2,1-a]Isoquinoline Derivative as Anticancerous Drug Candidate Against it. (Pubmed Central) - Jun 28, 2019
The results obtained from the present studies conclude that membrane protein is an efficient drug that can be used to target cancer. Moreover, comparative study with ADMET prediction concludes that isoquinoline can be a potent drug for cancer treatment.
- | Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
Review, Journal: Ceritinib Alone for Crizotinib-naive Versus Crizotinib-pretreated for Management of Anaplastic Lymphoma Kinase-rearrangement Non-Small-cell Lung Cancer: A Systematic Review. (Pubmed Central) - Jun 28, 2019
Ceritinib is an effective agent for both crizotinib-naive and crizotinib-pretreated patients with locally advanced or metastatic ALK-rearranged NSCLC. Ceritinib has significant activity in crizotinib-naive patients with brain metastases.
- | Clinical, Reimbursement, Review, Journal: Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions. (Pubmed Central) - Jun 26, 2019
For drugs whose authorization is based on prospective case series, most applications for reimbursement within public health care are granted. The underlying evidence has limitations over and above the design per se, and decision modifiers are frequently referred to in the value-based pricing decision making.
- | Zykadia (ceritinib) / Novartis, R-(-)-gossypol (AT 101) / Ascenta
Journal: Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma. (Pubmed Central) - Jun 24, 2019
Residual BRAFi and ALKi dual resistant melanoma cells from ceritinib-treated mice were sensitive to a broad-spectrum anti-apoptotic protein inhibitor, AT101. Collectively, our results provide a framework for treating BRAF-mutant melanoma that sequentially uses different targeted therapies based on post-treatment tumor evolution.
- | Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
Clinical, Journal: Capture-based ultra-deep sequencing in plasma ctDNA reveals the resistance mechanism of ALK inhibitors in a patient with advanced ALK-positive NSCLC. (Pubmed Central) - Jun 20, 2019
Collectively, our results provide a framework for treating BRAF-mutant melanoma that sequentially uses different targeted therapies based on post-treatment tumor evolution. Clinical evidence and in vitro validation revealed the clinical usefulness of captured-base ultra-deep sequencing on longitudinal plasma ctDNA in revealing the underlying resistance mechanism and guiding the precise administration of ALK inhibitors in patients with advanced ALK-positive NSCLC.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Journal: ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma". (Pubmed Central) - Jun 20, 2019
Despite its central nervous system tropism, ALK-rearranged adenocarcinoma manifesting with pituitary gland involvement was never reported. Second generation ALK inhibitors seem the best therapeutic strategy.
- | Retrospective data, Journal, Adverse events, Serious adverse event: The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis. (Pubmed Central) - Jun 14, 2019
According to this meta-analysis, alxectinib seems to be the safest ALK inhibitor. Physicians should focus on the related SAEs when prescribing ALK inhibitors.
- | Retrospective data, Journal: Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis. (Pubmed Central) - Jun 11, 2019
Five randomized studies assessed the intracranial efficacy of anti-ALK agents versus chemotherapy, the pooled RR for iORR was 3.54 (95% CI: 2.38-5.26), and the pooled HR for iPFS was 0.52 (95% CI: 0.36-0.75; P=0.71) estimated in 2 studies. Despite the limitation from lack of published clinical data, our results showed that ALK inhibitors are effective at the brain site regardless of previous anti-ALK treatments, systemic therapy with ALK inhibitors should be considered as a preferred approach over for controlling BMs from ALK-positive NSCLC.
- | Zykadia (ceritinib) / Novartis
Clinical, Journal: Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib. (Pubmed Central) - Jun 7, 2019
Clinical follow-up after 21 months treatment revealed complete clinical remission including all metastatic sites. Therefore, ceritinib presents a viable therapeutic option for ALK-positive neuroblastoma.
- |||| Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda
Activity of Brigatinib in Crizotinib & Ceritinib-Resistant @ros1cancer ROS1 #NSCLC #LCSM #LungCancer @JCO_ASCO #JCOPO @CancerMedMDA @notahedge @LungMAP https://t.co/5TWCWKUwBX (Twitter) - Jun 6, 2019
- | Zykadia (ceritinib) / Novartis
Journal: Insight on mutation-induced resistance to anaplastic lymphoma kinase inhibitor ceritinib from molecular dynamics simulations. (Pubmed Central) - May 31, 2019
An important hydrophobic cluster is identified that connects P-loop and the αC-helix, which has effects on stabilizing the conformation of ATP-binding pocket. It is suggested, in this study, that the G1123S and F1174C mutations can induce the conformational change of P-loop thereby causing the reduced ceritinib affinity and causing drug resistance.
- ||||| Zykadia (ceritinib) / Novartis
Clinical: Still impressive ORR among pre-treated patients. This compares VERY favorably to any available agents to my knowledge. The study of ceritinib had to stop including criz pretreated patients due to lack of efficacy. These data are thus very meaningful #LCSM #ASCO19 (Twitter) - May 31, 2019
- | Trial completion, Enrollment change: Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma (clinicaltrials.gov) - May 31, 2019
P2, N=1, Completed, Sponsor: University of California, San Francisco
It is suggested, in this study, that the G1123S and F1174C mutations can induce the conformational change of P-loop thereby causing the reduced ceritinib affinity and causing drug resistance. Recruiting --> Completed | N=44 --> 1
- | Zykadia (ceritinib) / Novartis, Pomalyst (pomalidomide) / Celgene
Journal: Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). (Pubmed Central) - May 29, 2019
We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1. In addition, proteomic profiling demonstrated that these compounds also promote the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).
- | Zykadia (ceritinib) / Novartis
Journal: Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. (Pubmed Central) - May 29, 2019
Aiming to identify novel potent ALK and ROS1 dual inhibitors, the relatively bulky piperidine fragment in ceritinib was replaced with substituted imidazolidin-2-one moiety which gave rise to a series of 2,4-diaryl-aminopyrimidine (DAAP) analogs (6-33)...Importantly, pharmacokinetic (PK) profiles of 15 were obtained with quite satisfying AUC and C values. Besides, the binding models of 15 with ALK, ALK and ROS1 clearly present the essential interactions within the active site.
- | SHP099 / Novartis, Lorbrena (lorlatinib) / Pfizer, Zykadia (ceritinib) / Novartis
Journal: SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. (Pubmed Central) - May 22, 2019
Treatment with SHP099, the recently discovered small-molecule inhibitor of SHP2, in combination with the ALK tyrosine kinase inhibitor (TKI) ceritinib halted the growth of resistant PDCs through preventing compensatory RAS and ERK1 and ERK2 (ERK1/2) reactivation. These findings suggest that combined ALK and SHP2 inhibition may be a promising therapeutic strategy for resistant cancers driven by several different ALK-independent mechanisms underlying resistance.
- | Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
Journal: Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma. (Pubmed Central) - May 17, 2019
Flow cytometry analysis indicated that ceritinib induced HepG2 and HCCLM3 cells apoptosis. ALK inhibitor exhibited antitumor effects by inhibiting ALK activation, repressing AKT and ERK pathways, and suppressing antiapoptotic gene expressions, which subsequently promoted apoptosis and suppressed HCC cell proliferations.
- |||| Lorbrena (lorlatinib) / Pfizer, Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
Clinical: .@MSPneu highlights that results in pts w/ROS1 driver mutations who receive targeted therapies like crizotinib, ceritinib, lorlatinib, & others are too good to miss these opportunities. These patients must be identified & treated appropriately. Many promising new agents. (Twitter) - May 16, 2019
- ||| Zykadia (ceritinib) / Novartis
Trial completion: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - May 15, 2019
P1, N=83, Completed, Sponsor: Novartis Pharmaceuticals
ALK inhibitor exhibited antitumor effects by inhibiting ALK activation, repressing AKT and ERK pathways, and suppressing antiapoptotic gene expressions, which subsequently promoted apoptosis and suppressed HCC cell proliferations. Active, not recruiting --> Completed
- | Zykadia (ceritinib) / Novartis
Journal: Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). (Pubmed Central) - May 9, 2019
Among these molecules, TD-004 effectively induced ALK degradation and inhibited the growth of ALK fusion positive cell lines, SU-DHL-1 and H3122. We also confirmed that TD-004 significantly reduced the tumor growth in H3122 xenograft model.
- | Zykadia (ceritinib) / Novartis
Clinical, Journal: Ceritinib Aggravates Glycemic Control in Insulin-treated Patients with Diabetes and Metastatic ALK-positive Lung Cancer. (Pubmed Central) - May 7, 2019
Ceritinib can aggravate hyperglycemia in patients with diabetes who lack compensatory insulin secretion, due to its inhibitory effects on the insulin receptor. Careful monitoring for ceritinib-induced hyperglycemia should be performed, especially in the first two weeks after ceritinib administration.
- |||| Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant @ros1cancer - Rearranged #NSCLC #lungcancer #LCSM @notahedge @DavidHongMD @MDAndersonNews https://t.co/7Uj4sKQ1i9 @JCO_ASCO #jcopo (Twitter) - May 3, 2019
- | Biomarker, Journal, PD(L)-1 Biomarker, IO Biomarker: Tissue and Blood Biomarkers in Lung Cancer: A Review. (Pubmed Central) - May 2, 2019
For predicting response to single agent pembrolizumab in the first-line treatment of patients with advanced adenocarcinoma or squamous cell NSCLCs, PD-L1 should be measured by an approved assay (e.g., PD-L1 IHC 22C3 pharmDx method)...Serum biomarkers may also be of use in determining prognosis and monitoring response to systemic therapies. With the increasing use of biomarkers, personalized treatment especially for patients with adenocarcinoma-type NSCLC is finally on the horizon.
- | Clinical, Journal: Treatment of ALK-positive nonsmall cell lung cancer: recent advances. (Pubmed Central) - Apr 26, 2019
Our review will discuss the recent phase III data with ceritinib and alectinib as well as clinical trials with other ALK inhibitors. We will also address two important issues in the management of ALK-positive NSCLC, prevention and treatment of brain metastases and management of emergent ALK-TKI resistance mechanisms.
- || Zykadia (ceritinib) / Novartis
Enrollment closed: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (clinicaltrials.gov) - Apr 25, 2019
P1, N=83, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
We will also address two important issues in the management of ALK-positive NSCLC, prevention and treatment of brain metastases and management of emergent ALK-TKI resistance mechanisms. Recruiting --> Active, not recruiting
- | Zykadia (ceritinib) / Novartis
Enrollment closed, Enrollment change, Combination therapy, Metastases: Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 19, 2019
P1, N=38, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=96 --> 38
- || Zykadia (ceritinib) / Novartis
Enrollment closed, Metastases: ASCEND-8: Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 19, 2019
P1, N=307, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=96 --> 38 Recruiting --> Active, not recruiting
- | Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
Journal, Heterogeneity: Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. (Pubmed Central) - Apr 17, 2019
Survival analysis of patients treated with targeted ALK inhibitors demonstrates a significant difference in mean survival between patients with next-generation sequencing confirmed EML4-ALK rearrangements, and those without (20.6 months vs 5.4 months, P<0.01). Together, these data demonstrate abundant genomic heterogeneity among ALK-rearranged lung adenocarcinoma, which may account for differences in treatment response with targeted ALK inhibitors.Modern Pathology advance online publication, 12 January 2018; doi:10.1038/modpathol.2017.181.
- ||| Zykadia (ceritinib) / Novartis
Enrollment change, Metastases: Ceritinib Rare Indications Study in ALK+ Tumors (clinicaltrials.gov) - Apr 16, 2019
P2, N=22, Completed, Sponsor: Novartis Pharmaceuticals
Together, these data demonstrate abundant genomic heterogeneity among ALK-rearranged lung adenocarcinoma, which may account for differences in treatment response with targeted ALK inhibitors.Modern Pathology advance online publication, 12 January 2018; doi:10.1038/modpathol.2017.181. N=106 --> 22
- | Biomarker, Enrollment open: NRG-LU003: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 16, 2019
P2, N=660, Recruiting, Sponsor: National Cancer Institute (NCI)
N=106 --> 22 Not yet recruiting --> Recruiting
- || Lorbrena (lorlatinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda
I’m guessing for the middle arrow it implies lorlatinib or brigatinib/ceritinib? Because at this time not sure any molecular feature would preclude lorlatinib except for L1198F or maybe off target MET amp? (Twitter) - Apr 12, 2019
- | Clinical, Review, Journal: Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review. (Pubmed Central) - Apr 11, 2019
Most of adverse effects of ALKi can be managed efficiently via dose modifications or interruptions. Timely identification of each ALKi pattern of toxicity can prevent treatment-related morbidity and mortality in this palliative setting.
- | Clinical, Review, Journal: Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature. (Pubmed Central) - Apr 10, 2019
...Crizotinib was responsible for pulmonary adverse events (AEs) in 1.8% of exposed patients (49 of 2706)...Pulmonary AEs during therapy with ceritinib, alectinib, and lorlatinib occurred in 1.1%, 2.6%, and 1.8% of the patients, respectively...Lung toxicity is a rare albeit potentially severe side effect in NSCLC patients receiving ALK-TKIs, apparently more frequent with brigatinib. Its early recognition and treatment are crucial for the best outcome of this subgroup of patients, whose overall prognosis is being improved by the availability of several targeted agents.
- ||| Zykadia (ceritinib) / Novartis
Enrollment change, Metastases: Ceritinib Rare Indications Study in ALK+ Tumors (clinicaltrials.gov) - Mar 5, 2019
P2, N=106, Completed, Sponsor: Novartis Pharmaceuticals
Its early recognition and treatment are crucial for the best outcome of this subgroup of patients, whose overall prognosis is being improved by the availability of several targeted agents. N=22 --> 106
- | Trial primary completion date: High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (clinicaltrials.gov) - Mar 4, 2019
P=N/A, N=25, Recruiting, Sponsor: University of Washington
N=22 --> 106 Trial primary completion date: Jul 2019 --> Jul 2020
- ||| Zykadia (ceritinib) / Novartis
Enrollment open, Metastases: Ascend-7: A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (clinicaltrials.gov) - Feb 25, 2019
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2019 --> Jul 2020 Completed --> Recruiting
- ||| Zykadia (ceritinib) / Novartis
Trial completion, Metastases: Ascend-7: A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (clinicaltrials.gov) - Feb 19, 2019
P2, N=160, Completed, Sponsor: Novartis Pharmaceuticals
Completed --> Recruiting Recruiting --> Completed
- ||| Alunbrig (brigatinib) / Takeda
Enrollment open, Metastases: ALTA-2: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (clinicaltrials.gov) - Feb 19, 2019
P2, N=103, Recruiting, Sponsor: Ariad Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Zykadia (ceritinib) / Novartis
Trial completion date, Combination therapy, Metastases: Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 1, 2019
P1, N=96, Recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Trial completion date: Jan 2019 --> Jan 2020
- ||| Zykadia (ceritinib) / Novartis
Enrollment open, Metastases: ASCEND-8: Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jan 22, 2019
P1, N=318, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jan 2019 --> Jan 2020 Active, not recruiting --> Recruiting
- || Zykadia (ceritinib) / Novartis
Trial primary completion date, Metastases: Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer (clinicaltrials.gov) - Jan 17, 2019
P2, N=100, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2019 --> Dec 2020
- | Zykadia (ceritinib) / Novartis
Trial completion date: Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 16, 2019
P1, N=86, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Feb 2019 --> May 2020
- | Zykadia (ceritinib) / Novartis
Trial completion date, Trial primary completion date: An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement (clinicaltrials.gov) - Jan 11, 2019
P2, N=32, Recruiting, Sponsor: Yonsei University
Trial completion date: Feb 2019 --> May 2020 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Zykadia (ceritinib) / Novartis
Enrollment open, Trial initiation date, Trial primary completion date: A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement (clinicaltrials.gov) - Jan 11, 2019
P2, N=46, Recruiting, Sponsor: Yonsei University
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Dec 2019 --> May 2020
- | New P3 trial, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov) - Dec 21, 2018
P3, N=960, Not yet recruiting, Sponsor: Institut National de la Sant